

# BIO, PhRMA Ask Fed. Circ. to Revisit Double-Patent Ruling

PUBLICATIONS | LESS THAN 1 MIN READ

July 14, 2014

By: Aaron Vehling


Law360

Axinn associate Thomas Hedemann, who represents Natco, was mentioned in Aaron Vehling's article, "BIO, PhRMA Ask Fed. Circ. to Revisit Double-Patent Ruling," which appeared on *Law360*.

Click [here](#) to access the article. A subscription is required.

## Related People

---



Thomas K. Hedemann

To subscribe to our publications, [click here](#).

## Featured Insights

- American Bar Association 2025 Asia-Pacific Conference  
**SPEAKING ENGAGEMENT    ANTITRUST**
- NBA Commercial Law Section 38th Annual Corporate Counsel Conference  
**SPONSORSHIP    ANTITRUST**
- GCR Live: Law Leaders Global 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- The 32nd Annual Marketing Partner Forum  
**EVENT**
- SABA North America Corporate Counsel Retreat 2025  
**SPONSORSHIP    ANTITRUST**
- Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2025  
**CLIENT ALERTS    ANTITRUST**
- Four Axinn Thought Leadership Pieces Nominated for the Antitrust Writing Awards  
**AWARDS & RECOGNITIONS    ANTITRUST**
- Merger Remedies Back in Vogue Under Trump  
**MEDIA MENTIONS    ANTITRUST**
- Three Takeaways from the Initial Determination at the ITC Regarding Standard Essential Patents in the 1380 Investigation  
**AXINN VIEWPOINTS    INTELLECTUAL PROPERTY**
- A POSA's Motivation Is Not Required To Be the Same as the Inventor's in Evaluating Obviousness  
**AXINN VIEWPOINTS    INTELLECTUAL PROPERTY**

